Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
| Status: | Archived |
|---|---|
| Conditions: | Ovarian Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2008 |
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients
with metastatic or locally advanced platinum-resistant ovarian cancer.
Patients will be randomized 1:1 into one of two treatment arms. NKTR-102 will be
administered at a dose level of 145 mg/m2 in both arms. In Arm A, NKTR-102 will be given on
a q14d schedule. In Arm B, NKTR-102 will be given on a q21d schedule. Approximately 70
patients may be evaluated in this study with approximately 35 patients in each treatment
arm.
We found this trial at
5
sites
Click here to add this to my saved trials
1309 North Flagler Drive
West Palm Beach, Florida 33401
West Palm Beach, Florida 33401
Click here to add this to my saved trials
Click here to add this to my saved trials
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials
Click here to add this to my saved trials